HEAD & NECK CANCERS

Cabanillas says her and her team set a goal of reducing the time between when they are contacted about a patient with anaplastic thyroid cancer, and when the patient is given an appointment time, to fewer than 5 business days.

Zevallos says that while HPV-positive oropharyngeal SCC has a positive outcome for patients, smoking status should be taken into account for these patients when making a decision to deintensify therapy.

Melotek says the trial's primary endpoint was comparison of efficacy when cetuximab is added to both therapies with historical control, with a secondary endpoint being further investigation of the usefulness of both chemotherapy platforms.

Seiwert says in general, immunotherapies produce a response rate of between 20- to 25%, 1 in 4 patients respond, and the treatment type is equally effective in both HPV-positive and HPV-negative disease.

In an interview, Frakes discusses a recent study and the impact these data have on follow-up frequency and the overall treatment paradigm for patients with OPSCC.

Biomarkers ultimately hold the key to improving both progression-free survival and overall survival with second-line afatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma.

A neoadjuvant combination of motolimod plus cetuximab was found to increase the immune responses in both the blood and tumor microenvironment for patients with head and neck squamous cell carcinoma.

The use of induction chemotherapy for advanced head and neck squamous cell carcinoma (HNSCC) does not improve overall survival (OS) when compared to concurrent chemotherapy plus radiation.

The 5-year overall survival (OS) in elderly patients with locally advanced head and neck cancers was drastically improved with concurrent chemoradiation versus radiation therapy alone, according to an analysis of the National Cancer Data Base.

Patients with HPV-positive oropharyngeal squamous cell cancer (OPSCC) who smoke can develop tobacco-associated mutations over time. These accumulated mutations result in less dependence on E6/E7 and other HPV-associated mutations.

Barbara Burtness, MD, discusses the explosion of immunotherapies on the horizon for patients with metastatic head and neck cancer.

Anaplastic thyroid cancer is an extremely aggressive form of cancer that cannot be cured by surgery and has a median survival of about 6 months. The malignancy normally occurs in patients over the age of 60, and there is not a standard of care, according to John A. Copland III, PhD, professor, Cancer Biology, Mayo Clinic.

Patients with a certain type of oral human papilloma virus (HPV) have an increased risk of developing head and neck squamous cell carcinoma, as well as oropharyngeal cancer, according to a new study.

With the phase III CheckMate-141 trial being stopped early due to the anti-PD-1 agent nivolumab having met its primary endpoint of overall survival improvement in head and neck cancer, Robert Ferris, MD, PhD, couldn't be more elated.

Anti–PD-1 agent nivolumab boosted overall survival versus an investigator's choice of therapy in platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) during a recent trial.

The FDA has granted an affinity enhanced T-cell therapy breakthrough therapy designation for patients with inoperable or metastatic pretreated synovial sarcoma who harbor HLA-A*201, HLA-A*205, or HLA-A*206 alleles and whose tumors express the NY-ESO-1 tumor antigen

Single-dose fosaprepitant dimeglumine (Emend for injection) in combination with antiemetic agents has been approved by the FDA for the preventing

Pembrolizumab (Keytruda), a PD-1 inhibitor, showcased encouraging activity with some adverse events (AEs) when employed as a treatment for patients with advanced PD-L1

Patients who elect to undergo immediate surgery for low-risk thyroid-related microcarcinoma may be subjecting themselves to unnecessary risk, according to findings from a large study in Japan.

The presence or absence of certain serum-free fatty acids could be an excellent diagnostic tool to differentiate between patients with either benign thyroid diseases or thyroid cancer.

An upcoming phase I trial seeks to evaluate a combination of interferon gamma-1b (ACTIMMUNE) and nivolumab (Opdivo) in patients with advanced solid tumors who have progressed on at least one prior systemic therapy.

The FDA has approved a new treatment consisting of a non-alcohol formulation of docetaxel in patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

Patients with newly-diagnosed glioblastoma who received treatment with tumor- treating electrical fields in addition to temozolomide had nearly double the two-year survival of those who received temozolomide alone, according to an article published in the Journal of the American Medical Association.

Rindopepimut is the first immunotherapy to have ever shown a survival benefit in brain cancers, specifically glioblastoma, said David Reardon, MD.

A chimeric antigen receptor T-cell therapy used in patients with EGFRvIII-positive glioblastoma multiforme during a pilot study showed promising results, according to two leading researchers in the field presenting at the 2015 Society of Neuro-Oncology Annual Meeting.